In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Vanguard Medica to develop SmithKline's antimigraine drug

Executive Summary

Vanguard Medica will develop SmithKline Beecham's antimigraine compound SB 209509. Vanguard will also be responsible for all US and European clinical trials, and will receive milestone payments, a share of profits, and US co-promotion rights.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R+D and Marketing-Licensing

Related Companies

UsernamePublicRestriction

Register